鶹ý

NSCLC: Contemporary Insights

MedpageToday

Video: Tackling Multiple Types Of Lung Cancer

—If a patient presents with multiple lung cancers, which should be treated first? The choice puts you at a disadvantage, explains Laurie Matt-Amaral, MD, of Cleveland Clinic. Here's what she recommends. (1:47)

Published:

image
Survival in T3 NSCLC May Differ With Chest Wall Infiltration
This retrospective analysis found that overall survival in NSCLC was significantly worse among patients with T3 tumors characterized by parietal pleura infiltration or chest wall infiltration than those characterized by size or the presence of a separate tumor nodule in the same lobe.
image
Promising Horizons In Non-Small Cell Lung Cancer
"The tide is turning," says Laurie Matt-Amaral, MD, of Cleveland Clinic. Recent advances in the field of NSCLC are changing the landscape of the disease. (1:10)
image
In NSCLC, How Does Tumor Microenvironment Affect Treatment?
Is there something that we can control? That's the question at heart when analyzing the tumor microenvironment, explains Laurie Matt-Amaral, MD, of Cleveland Clinic. In this video, she breaks down the components of the tumor microenvironment and how it's used to guide treatment. (2:58)
image
Emerging Biomarkers in NSCLC
Laurie Matt-Amaral, MD, of Cleveland Clinic, discusses HER3, cMET, and more, and where she sees the field heading in the future. (1:33)
image
Recurrent Metastatic NSCLC vs De Novo Stage IV: How Do Survival Rates Compare?
A study found that patients with distant recurrent metastatic non-small cell lung cancer had significantly better overall survival than those with de novo stage IV disease. These results may help inform clinical trial designs to ensure balanced baseline characteristics.
image
Detecting Lung Cancer: Is This A Better Way?
A lung cancer screening test examining small noncoding RNAs has demonstrated the ability to identify lung cancer using whole blood collected in the clinical setting, making it a potential alternative to low-dose computed tomography.